Moxifloxacin

CHEMBL32 Phase 4 معتمد Small molecule
Half-Life
12 hours
Bioavailability
Protein Binding
Molecular Weight
401.4 g/mol
LogP
0.6
Phase
4

This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.

الوزن الجزيئي

401,4350 g/mol

LogP

0,60

TPSA

82,10 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

تصنيفات الأدوية

آلية العمل

Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

الآلية

Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12

InChI

InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

Molecular Formula

C21H24FN3O4

HBD / HBA

2 / 8

الروابط القابلة للدوران

4

الذرات الثقيلة

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.

Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

Key pharmacokinetic parameters for Moxifloxacin: Half-life: 12 hours.

Yes, Moxifloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL32. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 152946. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.